Topline Ad­cetris da­ta in blood can­cer could mean new in­di­ca­tion for Pfiz­er

Pfiz­er is gun­ning for an eighth in­di­ca­tion for its Take­da-part­nered an­ti­body drug con­ju­gate Ad­cetris fol­low­ing pos­i­tive Phase III da­ta in blood can­cer.

Topline da­ta re­leased Tues­day showed that in pa­tients with re­lapsed/re­frac­to­ry dif­fuse large B-cell lym­phoma (DL­B­CL), Ad­cetris com­bined with chemother­a­py and Rit­ux­an showed a “sta­tis­ti­cal­ly sig­nif­i­cant and clin­i­cal­ly mean­ing­ful” im­prove­ment in over­all sur­vival.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.